Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-22T07:48:35.640Z Has data issue: false hasContentIssue false
  • English
  • Français

Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study -- CORRIGENDUM

Published online by Cambridge University Press:  17 May 2021

Christoph U. Correll ,
Robert L. Findling ,
Michael Tocco ,
Andrei Pikalov ,
Ling Deng  and
Robert Goldman
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Corrigendum
Information
CNS Spectrums , Volume 27 , Issue 1 , February 2022 , pp. 129
Copyright
© The Author(s), 2021. Published by Cambridge University Press

In the above articleReference Correll, Findling, Tocco, Pikalov, Deng and Goldman1 , Figure 4 has been updated with the following:

References

Correll, C., Findling, R., Tocco, M., Pikalov, A., Deng, L., & Goldman, R. (2020). Safety and effectiveness of lurasidone in adolescents with schizophrenia: Results of a 2-year, open-label extension study. CNS Spectrums, 1–11. doi:10.1017/S1092852920001893 CrossRefGoogle Scholar